Education
Tesamorelin in Endocrine Research
A 44-amino-acid GHRH analog with a single hexenoic-acid modification that extends its kinetic profile — what that means in the lab, and how REPRIME verifies the molecule.
Tesamorelin is a 44-amino-acid synthetic analog of growth-hormone-releasing hormone. It differs from native GHRH by a single trans-3-hexenoic acid modification on the N-terminus, which protects the molecule from rapid enzymatic degradation. The result is a research peptide that activates the GHRH receptor with a half-life suitable for laboratory time scales rather than the minutes-long window of unmodified GHRH. (New to the molecule? Start with the entry-level tesamorelin explainer.)
Why the modification matters
Native GHRH is degraded by dipeptidyl peptidase-4 (DPP-4) within minutes of entering serum. Without modification, GHRH is a difficult research peptide to work with because the dose-response window is narrow and short, and small variations in timing produce large variations in observed effect.
Tesamorelin's N-terminal hexenoic-acid modification slows DPP-4 cleavage substantially. The kinetic profile becomes workable: researchers can study the GHRH axis without their entire signal being lost to first-pass degradation. The same degradation problem shaped CJC-1295, another modified GHRH analog, which REPRIME supplies paired with the GHRP ipamorelin.
Sequence and synthesis
Tesamorelin's full sequence is well-characterized in the peer-reviewed literature. Solid-phase synthesis of a 44-residue peptide demands attention to coupling efficiency at every position — a single skipped coupling produces a deletion peptide that may co-elute on HPLC. Identity confirmation by mass spectrometry and main-peak purity by HPLC are non-negotiable for research use, and REPRIME publishes both for every batch.
The 20 mg vial
Lyophilized at -20°C, 20 mg gives enough material for extended protocols. Reconstitute with sterile diluent immediately before use; do not store reconstituted solution for longer than the period specified on the COA. The HPLC report is updated per batch on the product page and the Certificates repository.
Positioning
Tesamorelin is research-grade material for endocrine and growth-hormone-axis studies. REPRIME does not market it for any non-research application and does not provide dosage or protocol guidance.